Silo Pharma Authorizes $1 Million Share Repurchase Program

Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors authorized a share repurchase program to acquire up to $1 million of the company’s common stock. This authorization allows the company to purchase shares on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations, and the program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion.

The company reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025, according to its quarterly report for the period ended Sept. 30, 2025. This share repurchase program represents a strategic use of capital that could potentially enhance shareholder value by reducing the number of shares outstanding, thereby increasing earnings per share and potentially supporting the stock price. For investors, such programs often signal management’s confidence in the company’s financial health and future prospects, suggesting that leadership believes the stock is undervalued or that returning capital to shareholders is a priority.

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories, positioning it at the intersection of cutting-edge medical research and financial innovation.

The announcement of this share repurchase program comes at a time when biopharmaceutical companies face significant capital allocation decisions between research and development investments and shareholder returns. By authorizing this program, Silo Pharma demonstrates a balanced approach to capital management, potentially providing stability to its stock while continuing to fund its developmental pipeline. The company’s latest news and updates relating to SILO are available in its newsroom at https://ibn.fm/SILO, providing investors with ongoing information about corporate developments and research progress.

Share repurchase programs like this one are subject to various market conditions and regulatory requirements, meaning the actual execution and impact may vary based on numerous factors. However, the authorization itself represents a significant corporate action that could influence investor perception and market dynamics for Silo Pharma’s stock. As the company continues to advance its therapeutic programs and manage its cryptocurrency treasury operations, this capital allocation decision reflects strategic planning aimed at optimizing shareholder value while maintaining the financial flexibility needed for ongoing research initiatives.